Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance

Amylx Pharmaceuticals IncTrade
Vanguard Growth Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Vanguard Growth Index Fund ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Vanguard Growth Index Fund ETF trades at $88.76. Which is the better fit depends on your goals.

AMLXVUG
Market Cap
$2.53B
Sector
HealthSector/Thematic
52-Week High
$24.19$90.29
52-Week Low
$7.82$70.00
Enterprise Value
$2.28B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Vanguard Growth Index Fund ETF

Vanguard Growth ETF (VUG) trades at $89.4, up 0.81% today, with a bullish technical signal driven by strong moving average support. Recent news highlights significant institutional buying interest, with multiple firms increasing stakes by over 500% in Q2 2026. The ETF focuses on large-cap growth stocks, offering broad exposure to innovative US companies.

Outlook remains positive given institutional accumulation and growth stock momentum, though an RSI of 95.06 on a 6-day basis indicates potential overbought conditions. Key risks include market volatility and sensitivity to interest rate changes, but long-term growth prospects appear solid based on historical performance and sector trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Vanguard Growth Index Fund ETF

VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.

Read more on VUG